Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Summary

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

Timeline

Start

2024-12-02

Primary completion

2026-11

Completion

2027-02

Drugs

Indications